Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2021
CureVac announces 2020 financial results and business updates
CureVac announced its financial results for the fourth quarter and full year 2020, along with business updates.
2021
CureVac prices follow-on public offering
CureVac announced the pricing of a follow-on public offering of 5,000,000 common shares at $90 per share, for approximately $450 million in gross proceeds. The offering was expected to close on February 1, 2021, subject to customary closing conditions.
2020
CureVac appoints Antony Blanc to two executive roles
CureVac announced that Antony Blanc was appointed Chief Business Officer and Chief Commercial Officer.
2020
CureVac appoints CEO and chief scientific officer
CureVac announced that Dr. Franz-Werner Haas was appointed CEO and that Igor Splawski joined its executive team as chief scientific officer with immediate effect.
2020
CureVac closes $640 million financing round
CureVac closed a $640 million private financing round, including a further $126 million from Qatar Investment Authority and unnamed new and existing investors.
2020
GSK and CureVac agree mRNA vaccine collaboration
GlaxoSmithKline and CureVac announced a strategic collaboration agreement covering the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens. CureVac's existing COVID-19 mRNA and rabies vaccine research programmes are excluded.
2020
German government announces planned investment for a 23% stake in CureVac
The German government announced that state-owned KfW would invest €300 million to acquire a 23% stake in CureVac. The report says the stated aim was to keep vaccine technology in Germany and prevent it from moving abroad.